Earnings News - Candlesense

bioAffinity Technologies Reports Second Quarter 2025 Results

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports Q2 2025 results; CyPath Lung revenues up 62% year-over-year in first six months of 2025

Are there any regulatory updates or reimbursements that could further accelerate CyPath Lung adoption? What is the analyst sentiment and target price adjustments following this earnings release? How did operating expenses and cash burn change in Q2 relative to the same period last year?

Symbol: BIAF

28 days ago

Read more businesswire

Volato Delivers Strong Q2 Earnings Accelerates Debt Reduction Ahead of Transformational Merger

ATLANTA--(BUSINESS WIRE)--Volato Group, Inc. (NYSE American: SOAR) ("Volato" or the "Company") today announced financial results for the second quarter ended June 30, 2025, reporting its second con...

What is the anticipated impact of the merger on Volato's operating margins and cost structure? Are there any disclosed details on the use of proceeds from the merger or any potential asset sales? What is the current debt reduction pace versus the company's stated targets, and how might this influence credit ratings?

Symbol: SOAR

28 days ago

Read more businesswire

The Arena Group Posts 67% Revenue Growth with Record Profits

NEW YORK--(BUSINESS WIRE)--The Arena Group Holdings, Inc. (NYSE American: AREN) (“Arena”), a technology platform and media company home to many of the nation's most recognizable media brands, inclu...

How does the valuation (P/E, EV/EBITDA, price‑to‑sales) of AREN compare to its direct competitors and the broader media/technology sector? What are the key risks and uncertainties mentioned in the MD&A that could affect future performance? How does the company’s cash position, debt levels, and liquidity compare to prior periods and to its peers?

Symbol: AREN

28 days ago

Read more businesswire

Falcon’s Beyond Reports Second Quarter 2025 Financial Results

ORLANDO, Fla.--(BUSINESS WIRE)--Falcon’s Beyond Global, Inc. (Nasdaq: FBYD) (“Falcon’s Beyond”, “Falcon’s” or the “Company”), a visionary leader in innovative and immersive storytelling through its...

What macro‑economic or industry trends (e.g., consumer spending on immersive experiences) could affect the sustainability of the reported growth? Are there any disclosed strategic initiatives, partnership announcements, or capital‑raising activities that could impact the stock’s upside or downside potential? What guidance, if any, did Falcon’s Beyond provide for Q3 2025 or the full fiscal year, and how might that influence market expectations?

Symbol: FBYD

28 days ago

Read more businesswire

LICT CORPORATION REPORTS Solid Second Quarter 2025

RYE, N.Y.--(BUSINESS WIRE)--LICT Corporation (“LICT” or the “Company”; OTC Pink®: LICT), an integrated provider of broadband and voice services, today announced its financial results for the quarte...

How might the broader macro‑economic environment and industry trends influence LICT's performance after this earnings report? Does the earnings release reveal any shifts in subscriber growth or churn rates that could affect long‑term valuation? What is the impact of the new leadership on LICT's capital expenditure plans and infrastructure expansion?

Symbol: LICT

28 days ago

Read more businesswire

CoreCard Corporation Reports Second Quarter 2025 Results

NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of innovative credit technology solutions and processing ser...

What is the outlook for the company's credit‑risk exposure and credit‑loss provisions in the upcoming quarters? Are there any changes to the dividend policy, share repurchase program, or other shareholder‑return initiatives? What is the market’s reaction to the release (stock price movement, trading volume) and what are the implied valuation changes?

Symbol: CCRD

28 days ago

Read more globenewswire

Avicanna Reports Q2 2025

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...

What is the expected impact of the Q2 results on the stock's valuation multiples (e.g., P/E, EV/Revenue) relative to industry peers? Were there any one‑time items or non‑recurring expenses that materially impacted the quarter's results? How does the reported sentiment score of 15 translate into market perception, and is there any risk of a sentiment shift?

Symbol: AVCN

28 days ago

Read more globenewswire

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dys...

How might this FDA approval influence analyst sentiment and target price revisions for ABEO? What guidance is management providing for Q3 and full‑year 2025 earnings after the FDA approval? Are there any outstanding regulatory or litigation risks that could affect the commercial rollout of ZEVASKYN™?

Symbol: ABEO

28 days ago

Read more globenewswire

Cassava Reports Q2 2025 Financials Results and Provides Business Update

AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments f...

What is the expected impact of the announced business update on the company’s competitive positioning within the CNS therapeutic market? Are there any risks highlighted in the update that could affect the company’s valuation or credit facilities? What is the market’s perception of Cassava’s long‑term growth prospects based on this release?

Symbol: SAVA

28 days ago

Read more globenewswire

Eltek Ltd. Reports Strong Second-Quarter 2025 Results

20% Quarter-over-quarter revenue growth; gross margin expands to 24% PETACH TIKVA, Israel, Aug. 14, 2025 /PRNewswire/ -- Eltek Ltd. (NASDAQ: ELTK), a global manufacturer and supplier of technologic...

How could macroeconomic factors (e.g., semiconductor demand, supply chain constraints) affect ELTK's growth trajectory after this earnings beat? Is there any guidance on capital expenditures, R&D spending, or potential acquisitions following the strong quarter? What are the implications of the earnings release for the company's valuation multiples (P/E, EV/EBITDA) relative to the sector?

Symbol: ELTK

28 days ago